All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Fenway Sports Group
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 22, 2021
Details:
ProMIS plans to accelerate progress toward a number of top priorities, including; Advancing the PMN310 monoclonal antibody into clinical testing; Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): N,N-Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
28% and 32% significant reductions in first and total strokes, respectively, Showed with VASCEPA compared to placebo and reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated CV risk.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): YTX-7739
Therapeutic Area: Neurology Product Name: YTX-7739
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
YTX-7739 prevented motor function deficits in the diseased mice after four months of YTX-7739 oral dosing compared to placebo-treated mice. YTX-7739 demonstrates pharmacological, physiological, and behavioral pre-clinical proof of concept in in vivo model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amniotic fluid derived stem cells
Therapeutic Area: Neurology Product Name: ImmCelz
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
Creative Medical Technology Holdings reported that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz IND for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
